Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2000

View Archived Issues

Sepracor reviews third quarter developments

Permax approved in Canada as monotherapy for PD

Aphios awarded grant for antiplaque research

Amylin moves AC-2993 to phase II for type 2 diabetes

Phase II trial results for Alprox-TD in ED announced by NexMed

New three-in-one approach to Parkinson's disease

SBIR grant awarded to MetaPhore for human septic shock study

Cistron and Celltech merger approved

Array BioPharma and Amgen to collaborate on phosphatase inhibitors

Merger of IGT Pharma and NTB creates new company focused on neuroprotection

Bayer seeks FDA approval for intravenous formulation of Avelox

Cilansetron moves into phase III for IBS

CPMP issues positive opinion for Prevenar

Maxamine protects against IL-2 toxicity in murine model

Effective dose range for MK-0663 in RA patients determined in large international trial

Casodex monotherapy associated with preservation of BMD and sexual interest

Enzo Biochem's oral HBV protein product highlighted at AASLD meeting

Preliminary clinical data on parenteral and oral BN-80915 presented at NCI-EORTC-AACR

Merck issued patent covering new anticoagulants

Selective factor Xa inhibitors designed by Cor Therapeutics researchers

Takara Shuzo identifies new anticancer tetrahydrofuran

Novel immunomodulators claimed by Abbott in patent literature

Roche's new antidiabetic agents act as glucokinase activators

New PDE3/4 inhibitors undergo extensive preclinical evaluation at Vernalis

Peptides from P&G are selective MC3 and/or MC4 receptor ligands

Neurogen discovers new series of compounds interacting with NK3 and/or GABA-A receptors

Preparation and use of aP2 inhibitors in diabetes and related conditions

GST P1-1-activated nitrogen mustard prodrug shows promise as cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...